Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Countering the rush out of Japan's discovery research sector, a few global pharmaceutical corporations are maintaining early research operations or even expanding their presence in this area.
You may also be interested in...
Discovery Research In Japan By Global Pharmaceutical Outfits: Evolving More Toward Partnerships? (Part 1 of 3)
Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some, instead, are relying more on partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this first article in a three-part series on the subject.
Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
TOKYO - Pfizer Japan says upon Pfizer's expected merger with Wyeth later this year, it will become the largest pharmaceutical company in Japan, surpassing Takeda Pharmaceutical